Hair Lice Drug May Reduce Risk Of Death From COVID-19 By 80%

Simple treatment for COVID-19 could cost less than $ 20 – and familiar to most elementary school nurses.

Ivermectin, a head lice drug, is being investigated as a potential treatment for coronavirus following a promising new study that has shown an 80% reduction in hospitalized COVID-19 deaths.

Only 8 out of 573 patients who received ivermectin died, compared to 44 out of 510 people who died after receiving a placebo.

An earlier study of the prescription antiparasitic drug, which costs between $ 17 and $ 43 for a treatment, according to GoodRx, found promising results in April – by removing all viral RNA within 48 hours of a single dose.

University of Liverpool virologist Andrew Hill called the new study “transformational” in the search for coronavirus therapy. His findings, based on data from more than 1,400 patients, were made public in a video posted to YouTube in which Hill discusses his findings in a live stream already broadcast. The research is currently awaiting peer review before being published.

“If we see these same trends seen consistently in other studies, then it’s really going to be a transformational treatment,” Hill said.

However, critics called Hill’s study conclusion premature, calling for more research before declaring ivermectin as an effective treatment – citing other buzzing methods that ultimately failed, such as hydroxychloroquine and tocilizumab.

“All we have are observational studies and clinician opinions,” University of Sydney Professor Andrew McLachlan said, The Daily Mail reported.

“Many current studies have small numbers of participants, weak study designs, and inconsistent (and relatively low) ivermectin dosing regimens, with ivermectin frequently being given in combination with other drugs.”